The Medical Letter on Drugs and Therapeutics
Nilotinib (Tasigna) for CML
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nilotinib (Tasigna) for CML
Nilotinib (Tasigna - Novartis), a tyrosine kinase inhibitor, has been approved by the FDA for treatment of Philadelphia chromosome-positive (Ph+) chronic or accelerated phase chronic myelogenous leukemia (CML) in patients resistant to or intolerant...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nilotinib (Tasigna) for CML
Article code: 1283b
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.